Autorisation d’accès précoce refusée à la spécialité TECENTRIQ (atezolizumab).
See also
Décision d'accès précoce
25/11/2022
eNrlWE1z2jAQvedXMNxlg/kIdAyZliYtM82UkjDt9MIIeQ2iQnL0QUh/fWVMWtIxTSKiS3NhjCS/XUtv3+4qPtusWGUNUlHBe9V6UKtWgBORUD7vVSfXF6hTPeufxEu8xnvLToNaUI+qFcKwUr1qPhvMAHMVfLv89B7s+yCr/ZNKLGZLIPrBOqMpCz5itbjEWb6mEq8FTSor0AuR9KqZ0dvRSqy0tF70b4X8oTJMIA53I/uzy2lzfzwOc7AnoBoF8hPm81JQ4E6YxEgJXA+whrmQd6XQmUzq06jbade7HScjVI1BCSMJjLBejKRY0wSSUlspZgqcjKS3yRXINQOdGykFD5dkpZzA8RJvxnAzLHf6rZ0d6I1GNVQ/7dRanXa73W203E5Z7m1VOX3sR4TZtNHo1tr1KAQeJkBoznLEo1oUoVqz2QoTEipYocSgqIm4WMNqJgFt5+0YEYzBHFACiGG0wEYDsj9CUr0dVJjbh0xIbR+QhNSo3doEVpjbxwRhQkChTNrQIfdIKrOuYJajaCCWWJLeOFJmlBtnnshC1eAh8T3ZkXDzKCkTqjKG74Klyly3Cktsp0FaefL3IfkXXEsrmMzu2V/43DAWPtPryU7OPHmcq+VAGEvBclW7GLtuxEDY4NgcPlE3IdabHRcpqJeD/Sl4eRIamRmjxFVprRYaUHoyHh4W2legUe+wgon0J1JfKU/ErXp58dsnmyfvtwfDHikoWi3n2P5umX0gH58bKTIIrSxSdYzaDXkqjtU5GyzlUPeh8r9HybZqFQQzOFC3IkcltuFxX2Z7C0B/wV1MlIJ+OL92Ze0XA/Luavu3FJomvd98c0tTPnKfjZGDjj8/4grh+WdHk5Jp1Dltdhpu/YyR5bq20DpTb8JwgVURd0EqX0sq3CuK/DV4XiqvohIt0okn12dFnfB00rjG/2N12bG9xu79XU9TakNLA0ecQ5EqvAn68Pzlc8SfRsOb26MHmubPzLYpwNqKk6+q0MzKS8KjspI9V34hrTh8TlN64NbtIC/jsLjx65/EYX7b1z/5BZZGuQ4=
epSgX2k5v6xLyHgb